Previous 10 | Next 10 |
Precigen Provides Latest Clinical Developments at Virtual R&D Update Event GERMANTOWN, Md. , Dec. 15, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve ...
Gainers: Anchiano Therapeutics (ANCN) +142%.BioCardia (BCDA) +87%.Prevail Therapeutics (PRVL) +81%.Solid Biosciences (SLDB) +36%.OncoCyte (OCX) +24%.Bridgetown (BTWN) +23%.Contango Oil & Gas (MCF) +22%.Immutep (IMMP) +22%.MicroVision (MVIS) +20%.Sio Gene Therapies (SIOX) +1...
Precigen to Host R&D Update Virtual Event on December 15th to Share Latest Clinical Developments GERMANTOWN, Md. , Dec. 8, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell ...
Precigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T® at the 62nd ASH Annual Meeting and Exposition GERMANTOWN, Md. , Dec. 7, 2020 /PRNewswire/ -- Precigen, Inc. , a biopharmaceutical company spec...
San Francisco, California--(Newsfile Corp. - December 4, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have sufficient ...
SAN FRANCISCO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges Precigen, Inc. (N ASDAQ : PGEN ) (f/k/a Intrexon) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have sufficie...
After 30 years of development, AquaBounty is ready to commercialize. A potential solution for growing demand for high quality food/protein. Disruptive technology to change the AquaCulture environment. Challenges ahead: Controversial GMO and funds for growth. For further ...
San Francisco, California--(Newsfile Corp. - December 2, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have sufficient losses t...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Precigen, Inc. (PGEN) Investors to December 4th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Its Attorneys SAN FRANCISCO , Dec. 1, 2020 /PRNewswire/ -- Hagens Berman urges Precigen, Inc. (NASD...
San Francisco, California--(Newsfile Corp. - November 29, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have sufficient losses ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...